Catalent to Acquire RheinCell Therapeutics
Catalent expands capabilities for stem cell-based therapies with acquisition of RheinCell’s GMP-grade human iPSCs.
Catalent announced on June 24, 2021 an agreement to acquire RheinCell Therapeutics GmbH, a Langenfeld, Germany-based developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs), further expanding its custom cell therapy process development and manufacturing capabilities.
In making the announcement, Catalent reported that the acquisition will allow it to offer the building blocks to scale iPSC-based cell therapies and reduce barriers to entry to the clinic for therapeutic companies.
iPSC cell types can address a number of therapeutic indications. RheinCell has researched and developed full GMP human leukocyte antigen-matched cell banks.
Upon closing, which is expected before the end of 2021, RheinCell’s current employees will join Catalent’s Cell & Gene Therapy business.
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
